INZY — Inozyme Pharma Balance Sheet
0.000.00%
- $104.59m
- $37.46m
Annual balance sheet for Inozyme Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 148 | 112 | 128 | 189 | 113 |
Net Total Receivables | 0.155 | 0.062 | 0.115 | 0.385 | 0.467 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 151 | 115 | 131 | 196 | 121 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 2.65 | 4.44 | 3.64 | 2.59 | 1.35 |
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 169 | 124 | 139 | 201 | 123 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 9.97 | 11.6 | 14.7 | 14.7 | 33.9 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 11.3 | 14.3 | 20.8 | 60.4 | 65.4 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 158 | 109 | 118 | 140 | 57.8 |
Total Liabilities & Shareholders' Equity | 169 | 124 | 139 | 201 | 123 |
Total Common Shares Outstanding |